Business context and reporting period
Filing identity discrepancy: The request identifies Opus Genetics, Inc., but the supplied Form 10-Q is for Rexahn Pharmaceuticals, Inc. It covers the quarter ended March 31, 2015, and was filed May 8, 2015. The filing describes Rexahn as a clinical-stage biopharmaceutical company focused on cancer treatments, with no commercial product revenue.
Rexahn reported one oncology candidate in Phase II, two in Phase I, and additional preclinical candidates. Its financial statements are unaudited interim statements.
Key financial metrics
| Metric | Q1 2015 | Q1 2014 or comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $2.893 million | $1.272 million |
| General and administrative expense | $1.525 million | $1.495 million |
| Operating loss | $4.418 million | $2.766 million |
| Net loss | $4.272 million; $0.02 per share | $14.600 million; $0.09 per share |
| Cash used in operating activities | $4.039 million | $2.577 million |
| Cash and cash equivalents | $10.729 million at March 31 | $9.826 million at December 31, 2014 |
| Marketable securities | $18.656 million at March 31 | $22.872 million at December 31, 2014 |
Cash plus marketable securities totaled $29.385 million at quarter-end, down from $32.698 million at December 31, 2014. Total liabilities were $7.104 million, including $3.653 million of warrant liabilities. The balance sheet presents no conventional borrowing line. Gross margin is not applicable because the company reported no revenue.
Material changes versus the prior comparable period
- R&D expense rose $1.621 million, or 127.5%, primarily from clinical-trial and drug-manufacturing costs for Archexin, RX-3117, and Supinoxin, as well as increased personnel costs.
- Operating loss widened by $1.652 million as operating expenses increased.
- Net loss improved substantially year over year, mainly because the prior-year quarter included an $11.661 million noncash unrealized warrant valuation loss; Q1 2015 instead recorded a $115,415 unrealized gain. The improvement does not reflect stronger operating performance.
- Operating cash use increased to $4.039 million from $2.577 million. Q1 2015 financing cash flow included $705,542 from option exercises; Q1 2014 included substantial offering and warrant-exercise proceeds.
Outlook, risks, and unusual items
- Management said cash, cash equivalents, and marketable securities were expected to cover cash-flow needs for current activities for at least the next 12 months, while also stating that additional capital would be needed to continue development. If financing is unavailable, the company may reduce R&D, beginning with preclinical programs.
- On March 16, 2015, Rexahn entered an at-the-market sales agreement allowing up to $40 million of common stock sales, subject to its terms; no shares had been sold under it by March 31. The sales agent commission is 3% of gross proceeds.
- Management expected to complete the initial safety component of the Archexin renal-cell-carcinoma study in the second half of 2015. It expected enrollment completion for RX-3117 and potentially Supinoxin in the first half of 2015; the maximum tolerated dose had not yet been reached for either program.
- The company reported an estimated $9.780 million cost to complete existing R&D vendor contracts. Clinical development, regulatory approval, external research-provider dependence, intellectual-property protection, and access to future financing are material risks. Management could not estimate the total cost or timing to complete development programs or when, if ever, product cash inflows might begin.
- Warrant liabilities are valued using a model with significant unobservable assumptions, including management’s estimated probability of a fundamental transaction; valuation changes can materially affect reported earnings without corresponding operating cash flows.
Most important facts for investors to verify
- Confirm the issuer: the supplied filing is Rexahn Pharmaceuticals, Inc., not Opus Genetics, Inc.
- Assess cash runway against the company’s stated 12-month coverage claim, planned clinical spending, and the $9.780 million estimated remaining R&D contract costs.
- Check subsequent use and availability of the $40 million ATM facility, including dilution and actual proceeds.
- Verify clinical-trial enrollment, safety, dose-escalation, and milestone progress against the stated expectations.
- Separate operating performance from noncash warrant remeasurement when evaluating the year-over-year net-loss comparison.